Issue link: http://www.e-digitaleditions.com/i/880535
A review of the three Respiratory Drug Delivery conferences: Respiratory Drug Delivery, RDD Europe and RDD Asia, and a preview of RDD 2018 in Tuscon, AZ. The Respiratory Drug Delivery Conferences: Feedback and the future The Organizers of the Respiratory Drug Delivery Conference Series delegates representing 16 countries was highly favorable, and we will be bringing RDD Asia 2018 to India, November 14-16, 2018. RDD in the United States RDD meetings in the United States are the most comprehensive and largest we arrange, and serve to highlight cutting-edge devel- opments presented by key scien- tists, engineers, clinicians, regula- tors and other opinion leaders. Discussions and collaborative op- portunities abound, due to the longer meeting duration and the diverse interests and expertise of meeting participants. To these ends, RDD 2018 (Tuc- son, Arizona, April 22-26, 2018) will feature: • In-depth discussions of devel- oping issues surrounding com- bination product design and crossover technologies, which resonate with the diverse exper- tise of our delegates from the drug delivery industry. • A scientific poster session and technology exhibition during which device and equipment designers and component sup- pliers will present their latest developments alongside scien- tific posters from the aerosol community. • Posters on the Podium, where innovative poster abstracts are featured as short podium pre- sentations during a special ses- sion in the main auditorium. • e Charles G. iel Award, presented to a scientist who has pioneered significant develop- ere are three Respiratory Drug Delivery (RDD) conferences ev- ery two years. Between confer- ences, the organizers work hard to respond to participants' feedback, and secure excellent speakers to address the most salient topics in pulmonary and nasal drug deliv- ery at future conferences. Large, diverse audiences attend RDD ® (in the United States), RDD Eu- rope, and RDD Asia to remain on top of important developments, share their scientific and commer- cial advances and meet collabora- tors and suppliers. RDD Europe RDD Europe 2017 (Antibes, France, April 25–28, 2017) was particularly successful by every one of these measures. Of the 500 par- ticipants in attendance, represent- ing more than 30 countries, ap- proximately 300 were new to RDD Europe. One wrote, "is was my first time at RDD. [I was] very impressed by the scientific quality of the meeting." e increasing worldwide partici- pation serves as an indicator of strong interest in our pharmaceuti- cal niche and a harbinger of new products entering the global mar- ket. Based on learning from RDD Europe 2017, it's likely some of these products will utilize advanced hardware, sophisticated formula- tion and fabrication approaches, and exhibit connectivity to address longstanding problems known to beset some patients receiving in- haled drug therapy. ese subjects, in addition to the topics of new drugs, product quality, advances in clinical and laboratory testing, and regulatory and legal issues will continue to be developed at RDD 2018 (Tuc- son, Arizona, US, April 22-26, 2018) and RDD Europe 2019 (Lisbon, Portugal, May 7-10, 2019). Driven by attendees' sug- gestions, we will continue to in- crease networking opportunities during the exhibition and poster sessions, meal breaks and social events, and expand the use of electronic question submission following podium presentations. RDD Asia RDD Asia 2016 (Goa, India, No- vember 8-11, 2016) was a smaller meeting designed to meet the needs of rapidly growing compa- nies keen to learn about the latest developments in nasal and pulmo- nary products, without the expense of visiting the United States or Eu- rope. We facilitated presentations by internationally known speakers that addressed the mechanics of powder dispersion in dry powder inhalers, advanced optical systems to probe pressurized metered dose inhaler spray development and powder fluidization, alongside talks that highlighted local research and treatment of COPD, TB and respiratory infections. e US FDA also presented an overview of inhalation device regulations and participated in a panel discussion related to "Advancing Regulatory Science of Inhaled Products." Learning was enhanced during an exhibition comprised of 30 com- panies, augmented by seven work- shop sessions and several scientific posters. Meeting feedback from Inhalation OctOber 2017 5 organizations Cross-industry